J CRAIG VENTER INSTITUTE INC

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

Address and contacts

Address (IRS master file)

950 WATERFRONT PL STE 500, SAN DIEGO, CA 92101-6182

In care of

% HEATHER KOWALSKI

Principal officer (990 for 2024)

JOHN CRAIG VENTER, 4120 CAPRICORN LANE, LA JOLLA, CA 92037

Signed the 990

JOHN CRAIG VENTER, CHAIRMAN AND CEO

Phone

(858) 200-1800

Website

WWW.JCVI.ORG

Return prepared by

BAKER TILLY ADVISORY GROUP LP

California records

California keeps its own records of charities and corporations. Search them by EIN 52-1842938 or by the name J CRAIG VENTER INSTITUTE INC.

Attorney General, Registry of Charities and Fundraisers

Registration status and filed reports (CT-TR-1, RRF-1)

Secretary of State, bizfile Online

Corporation status, entity number, agent for service

Franchise Tax Board

Entity status letter (state tax exemption, good standing)

Mission

J. CRAIG VENTER INSTITUTE (JCVI) IS AN INDEPENDENT 501(C)(3) NONPROFIT ORGANIZATION ADVANCING THE SCIENCE OF GENOMICS COMMITTED TO ACCELERATING FOUNDATIONAL SCIENTIFIC RESEARCH TO DRIVE ADVANCES IN HUMAN HEALTH AND ENVIRONMENTAL SUSTAINABILITY. THIS PAST YEAR JCVI COMMITTED RESEARCH EFFORTS IN HUMAN HEALTH, ENVIRONMENTAL SUSTAINABILITY, SYNTHETIC BIOLOGY, AND SOFTWARE TOOLS AND TECHNOLOGY.

Program accomplishments

• DEPARTMENT OF HEALTH AND HUMAN SERVICES: TWO MILLION PEOPLE IN THE U.S. ARE DIAGNOSED ANNUALLY WITH LIFE-THREATENING INFECTIONS CAUSED BY ANTIBIOTIC RESISTANT BACTERIA THAT ARE RESPONSIBLE FOR 35,000 DEATHS EACH YEAR WITH AN ECONOMIC IMPACT ESTIMATED TO BE AS MUCH AS $20 BILLION A YEAR IN DIRECT HEALTHCARE COSTS. DUE TO THE SPREAD OF ANTIBIOTIC RESISTANCE, VERY FEW DRUGS REMAIN THAT CAN TREAT THESE INFECTIONS. LED BY DERRICK FOUTS, PHD, (JCVI) AND FUNDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), THE J. CRAIG VENTER INSTITUTE AND CLEVELAND VA PREVENTION AND INTERVENTION EPICENTER ARE DEVELOPING NOVEL INTERVENTIONS THAT WILL PREVENT THE COLONIZATION AND SPREAD OF ANTIBIOTIC RESISTANT (AR) BACTERIA THAT CAUSE HOSPITAL ACQUIRED INFECTIONS (HAI), AND TO DEVELOP DIAGNOSTICS AND INTERVENTIONS TO COMBAT THE COLONIZATION BY THE RAPIDLY EMERGING FUNGAL PATHOGEN CANDIDA AURIS. COLLABORATORS ON THIS MULTI YEAR FUNDED CENTER INCLUDE RESEARCH LABS AT DUKE UNIVERSITY, CASE WESTERN UNIVERSITY AND NORTHWESTERN UNIVERSITY. LED BY INDRESH SINGH, DIRECTOR OF INFORMATICS, THE JCVI IS A KEY COLLOBORATOR FOR THE BACTERIAL AND VIRAL BIOINFORMATICS RESOURCE CENTER (BV-BRC). USING THE ADVANCED SYSTEM ARCHITECTURE BASED ON HIGH-PERFORMANCE COMPUTING, EXTENSIBLE DATABASE MANAGEMENT APPROACH STRUCTURED ON EMERGING METADATA STANDARDS, AND SUITE OF ANALYSIS AND VISUALIZATION TOOLS AND SERVICES AVAILABLE FOR CUSTOMIZED WORKFLOW ASSEMBLY JCVI SUPPORTS ONGOING DEVELOPMENT OF THE COMPREHENSIVE INTEGRATED BV-BRC THROUGH A TEAM OF VIROLOGY, IMMUNOLOGY, BIOINFORMATICS, AND INFORMATION TECHNOLOGY PROFESSIONALS WHO FOCUS ON THE DEVELOPMENT, ENHANCEMENT, AND TRAINING OF THE BV-BRC RESOURCE FOR THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, THEIR SUPPORTED RESEARCHERS, AND THE BROADER INFECTIOUS DISEASE RESEARCH COMMUNITY. INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE ARE INCREASINGLY PREVALENT AND DIFFICULT TO TREAT DUE TO INEFFECTIVE TREATMENT OPTIONS DUE TO INCREASED ANTIBIOTIC RESISTANCE. BACTERIOPHAGES, VIRUSES THAT INFECT AND KILL BACTERIA, ARE BEING USED TO EFFECTIVELY TREAT AND CURE INFECTIONS CAUSED BY A NUMBER OF BACTERIAL PATHOGENS. TO ADDRESS THE NEED FOR NEW TREATMENTS FOR WOUND AND PULMONARY INFECTIONS CAUSED BY K. PNEUMONIAE, DR. DERRICK FOUTS TEAM HAS DEVELOPED A 5-PHAGE LEAD CANDIDATE THERAPEUTIC COCKTAIL THAT IS CAPABLE OF INFECTING 53 OF OUR 100-STRAIN TEST PANEL. FUNDED BY THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, THE JCVI, THE WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) AND ADAPTIVE PHAGE THERAPEUTICS (APT) WILL OPTIMIZE THE LEAD THERAPEUTIC AND ITS PRODUCTION AS WELL AS CONDUCT THE REQUIRED PREINVESTIGATIONAL NEW DRUG (IND) TESTING AND BENCHMARKING NECESSARY FOR THE SUCCESSFUL SUBMISSION AND REVIEW OF AN IND APPLICATION FOR A PHASE 1 CLINICAL TRIAL. RESEARCH WILL LEVERAGE JCVI'S HISTORY OF SYNTHETIC AND PHAGE GENOMICS, WRAIR'S EXPERIENCE DEVELOPING PHAGE THERAPEUTICS, DEVELOPMENT OF MOUSE MODELS, AND APTS CGMP PRODUCTION CAPABILITIES AND EXPERIENCE WITH PHAGE CLINICAL TRIALS.
  Expenses $5,271,780 · grants $770,981
• NATIONAL SCIENCE FOUNDATION CONTINUES TO FUND THE J. CRAIG VENTER INSTITUTE (JCVI) IN THE AREAS OF SYNTHETIC BIOLOGY, INTEGRATIVE ORGANISMAL SYSTEMS CORE PROGRAMS. FUNDED BY THE OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING, DR. TAE SEOK MOON, JCVI PROFESSOR LEADS AN INTERNATIONAL CONSORTIUM THROUGH A GLOBAL CENTER TO ADDRESS THE CHALLENGES OF RECALCITRANT WASTE STREAMS BY DEVELOPING INTEGRATED, NOVEL, AND SCALABLE PROCESSES FOR THEIR VALORIZATION, INTEGRATING RESEARCHERS ALL OVER THE WORLD AND FROM ACADEMIA AND INDUSTRY, AND PROVIDING GLOBAL EDUCATION, OUTREACH ACTIVITIES, AND WORKFORCE. GLOBAL CENTERS: CIRCLE: CENTER FOR INNOVATIVE RECYCLING AND CIRCULAR ECONOMY IS SUPORTED BY RESEARCH TEAMS IN THE UNITED STATES, CANADA, UNITED KINGDOM, KOREA, JAPAN, SINGAPORE & AUSTRALIA. THIS CENTER WILL DEVELOP THREE CORE TECHNOLOGIES, INCLUDING (1) MULTI-OMICS-BASED BIOPROSPECTING TO DISCOVER NEW ENZYMES, GENE REGULATORS, AND ORGANISMS FOR WASTE VALORIZATION, (2) PREDICTIVE COMPUTATIONAL APPROACHES TO ENABLE FORWARD ENGINEERING OF PROTEINS AND STRAINS FOR BIOMANUFACTURING, AND (3) TEA, LCA, AND RISK ASSESSMENT TO DEVELOP COMMERCIALLY VIABLE BIOPROCESSES FOR WASTE VALORIZATION. TO DEMONSTRATE THE UTILITY AND GENERALIZABILITY OF THE DEVELOPED CORE TECHNOLOGIES, WE WILL DEVELOP COMMERCIALLY VIABLE VALORIZATION PROCESSES FOR THREE WASTE STREAMS, INCLUDING MIXED PLASTICS, C1 GASES, AND BIOGENIC WASTES (E.G., FOOD, AGRICULTURAL, AND PAPER/CARDBOARD WASTES). IF SUCCESSFUL, THESE HIGH-RISK, HIGH-RETURN CENTER PROJECTS WILL PROVIDE NOVEL WASTE CONVERSION PROCESSES THAT CAN BE CONSIDERED FOR COMMERCIAL-SCALE, SUSTAINABLE BIOPRODUCTION. THIS IS MULTI-YEAR INTERNATIONAL STUDY. THE US CONSORTIUM HAS BEEN FUNDED UPTO $4.9M. NON-US COLLABORATORS HAVE BEEN FUNDED THROUGH RESEARCH AGENCIES WITHIN THEIR OWN COUNTRIES. UNDER THE DIVISION OF MOLECULAR AND CELLULAR BIOSCIENCE AND IN COLLABORATION WITH THE UNIVERSITY OF ILLINOIS MINIMAL BACTERIAL CELL COMPUTATIONAL MODELEING TEAM LED BY ZAIDA LUTHEY-SCHULTEN, JCVI RESEARCHERS LED BY DR. JOHN GLASS, ARE CARRYING OUT TRANSCRIPTOME AND METABLOMIC ANALYSES, BIOCHEMICAL AND GENETIC EXPERIEMENTS TO DISCOVER UNKNOWN GENE FUNCTIONS, OPTIMIZATION OF A MINIMAL CELL DEFINED GROWTH MEDIUM, AND CONSTRCUTION OF MINIMAL CELL MUTATNS TO FACILITATE THE WORK OF JCVI AND OTHER GROUP[S INVESTIGATING MINIMAL CELL BIOLOGY. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $2.0M (~$0.7M JCVI).LED BY DR. JOHN GLASS, THE JCVI IS INVESTIGATING THE MECHANISM OF GENOME TRANSPLANTATION, DEVELOP GENOME TRANSPLANTATION FOR AT LEAST TWO SPECIES OF NON-MYCOPLASMA BACTERIA, AND USE MICROFLUIDICS TECHNOLOGY TO AUTOMATE AND IMPROVE THE EFFICIENCY OF GENOME TRANSPLANTATION. GENOME TRANSPLANTATION, THE INSERTION OF A COMPLETE BACTERIAL GENOME INTO A SUITABLE RECIPIENT CELL SO THAT THE DONATED GENOME COMMANDEERS THE RECIPIENT CELL TO PRODUCE A NEW CELL WITH THE GENOTYPE AND PHENOTYPE OF THE DONATED GENOME, WAS THE FUNDAMENTAL TECHNICAL DEVELOPMENT THAT ENABLED THE CONSTRUCTION OF THE FIRST BACTERIUM WITH A SYNTHETIC GENOME. AT THE ANNOUNCEMENT OF THE CREATION OF THE WORLD'S FIRST SYNTHETIC CELL, JCVI-SYN1.0, THE WORK WAS HERALDED AS A MAJOR ACCOMPLISHMENT FOR HUMANKIND. TO DATE, GENOME TRANSPLANTATION HAS ONLY BEEN ACHIEVED USING A SMALL SUBSET IF THE ATYPICAL BACTERIA CALLED MYCOPLASMAS. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $1.0M.
  Expenses $1,128,103 · grants $200,684
• JCVI SCIENTISTS HAVE PARTNERED WITH OTHER SCIENTISTS FROM LEADING ACADEMIC CENTERS TO COME TOGETHER TO ANSWER KEY QUESTIONS ABOUT THE ROOT CAUSE OF LONG COVID WHETHER FRAGMENTS OF THE CORONAVIRUS PERSIST IN THE TISSUES OF PATIENTS. THE LONG COVID RESEARCH INITITATIVE BANDS TOGETHER SCIENTSITS FROM HARVARD UNIBVERSITY, STANFORD UNIVERSITY, THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, YALE UNIVERSITY AND THE J. CRAIG VENTER INSTITUTE. THE INITITATIVE IS BACKED BY AN INITITIAL INVESTMENT FROM THE BALVI, A SCIENTIFC INVESTMENT FUND. JCVI FUNDING IS AWARDED THROUGH THE POLYBIO RESEARCH FOUNDATION. RESEARCHERS ARE USING ADVANCED IMAGING AND GENE-SEQUENCING TECHNIQUES LOOKING FOR EVIDENCE OF THE VIRUS IN TISSUES AND ANALYZING ITS AFFECT ON THE IMMUNE SYSTEM. OVER THE LAST FEW YEARS, ADVANCES IN STEM CELL RESEARCH AND SYNTHETIC BIOLOGY HAVE CATALYZED AN EXTRAORDINARY EXPANSION OF ORGANOID TECHNOLOGY THAT IS BRINGING CHANGES TO TRANSLATIONAL MEDICINE, PHARMACEUTICAL RESEARCH, AND STRATEGIES FOR TREATING VARIOUS HUMAN PATHOLOGIES. USING STEM CELLS, ORGANOIDS HAVE BEEN DEVELOPED FOR MULTIPLE ORGANS INCLUDING LIVER, INTESTINE, KIDNEY, BRAIN, STOMACH, SKIN, OVARY, AND LUNG. FUNDED BY THE LARRY L HILLBLOM FOUNDATION, DR. JOHN GLASS IS LEADING A CONSORTIUM OF RESEARCHERS THAT PROPOSE TO DEVELOP ORGANOIDS THAT CAN SERVE AS SURROGATES FOR BETA CELLS, WHICH ARE THE CELLS IN THE HUMAN PANCREAS THAT CONTROL BLOOD GLUCOSE LEVELS BY SYNTHESIZING INSULIN. OUR GOAL IS THAT THESE ORGANOIDS, WHEN IMPLANTED IN TYPE 1 DIABETICS, WILL RESULT IN A BETTER TREATMENT AND BETTER LIVES FOR THOSE PATIENTS.
  Expenses $2,066,947 · grants $565,153
• OTHER RELATED PROGRAMS FOR SUPPORT OF DEVELOPMENT OF KEY STAFF & INTERNSHIPS.
  Expenses $451,688

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

52-1842938

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Publicly supported organization (170(b)(1)(A)(vi))

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

1995

Accounting year ends

December

Files

Form 990 or 990-EZ

Category (NTEE)

Science and technology (U50Z)

Assets (IRS master file)

$39,462,295

Income (IRS master file)

$70,623,105

Filing history

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 52-1842938).

Questions about J CRAIG VENTER INSTITUTE INC

What is the EIN of J CRAIG VENTER INSTITUTE INC?

The employer identification number (EIN) of J CRAIG VENTER INSTITUTE INC is 52-1842938.

Is J CRAIG VENTER INSTITUTE INC tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1995.

Are donations to J CRAIG VENTER INSTITUTE INC tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does J CRAIG VENTER INSTITUTE INC file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of J CRAIG VENTER INSTITUTE INC due?

The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.

When did J CRAIG VENTER INSTITUTE INC last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended December 2024.

Who is the principal officer of J CRAIG VENTER INSTITUTE INC?

The 990 for the year ended December 31, 2024 names JOHN CRAIG VENTER.

Who are the officers and directors of J CRAIG VENTER INSTITUTE INC?

The 990 for the year ended December 31, 2024 lists 16 people; 11 received compensation from the organization, the highest $1,190,475 (VENTER JOHN CRAIG, CHAIRMAN & CHIEF EXECUTIVE OFFICER).

How much revenue does J CRAIG VENTER INSTITUTE INC have?

On its 990 for the year ended December 31, 2024 it reported revenue of $14,407,483, expenses of $19,604,869 and total assets of $39,462,295 at year end.

Other nonprofits in SAN DIEGO

• FAR AI INC
  EIN 92-0692207 · last filed 990 for 2024
• SAN DIEGO ASTRONOMY ASSOCIATION FOUNDATION
  EIN 99-2163812 · last filed 990 for 2025
• SCINTILLON INSTITUTE
  EIN 45-4323888 · last filed 990 for 2024
• INTERNATIONAL ASSOCIATION FOR SAFE AND ETHICAL ARTIFICIAL
  EIN 32-0790930 · last filed 990 for 2025
• FOUNDATION FOR ANIMAL CARE ANDEDUCATION
  EIN 20-5333261 · last filed 990 for 2024
• TREOBYTES INC
  EIN 46-3992953 · last filed 990 for 2025
• BIOCOM INSTITUTE
  EIN 26-1852884 · last filed 990 for 2024
• ELEMENTARY INSTITUTE OF SCIENCE
  EIN 94-1669545 · last filed 990 for 2025

All nonprofits in SAN DIEGO · California · Science and technology